Clinical Trial Update: A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis [Phase 2]

View source ↗

Summary

Phase 2 dose-escalation trial evaluating pulsed inhaled nitric oxide for safety and efficacy in pulmonary fibrosis and sarcoidosis (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis
• Pulmonary Hypertension
• Sarcoidosis Pulmonary

Drugs mentioned

• pulsed inhaled nitric oxide (nitric oxide)

Snippet

Sponsor: Bellerophon | Conditions: Pulmonary Hypertension, Pulmonary Fibrosis | Phase 2 | Status: COMPLETED